Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yves Beguin

Showing results (161-170 of 243) with videos related to

Pageof 25
Sort By:
Frontiers in Immunology|September 15, 2018
Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD MiceGrégory Ehx, Joan Somja, Hans-Jörg Warnatz, et al.
Oncotarget|May 15, 2018
Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective studySophie Servais, Frédéric Baron, Chantal Lechanteur, et al.
Haematologica|October 12, 2010
Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of ageEmilie Castermans, Muriel Hannon, Jacques Dutrieux, et al.
Haematologica|September 28, 2014
Circadian and circannual variations in cord blood hematopoietic cell compositionSophie Servais, Etienne Baudoux, Bénédicte Brichard, et al.
Oncotarget|April 21, 2016
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myelomaRoy Heusschen, Joséphine Muller, Marilène Binsfeld, et al.
Journal of Hematology & Oncology|February 6, 2015
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological SocietyFrédéric Baron, Pierre Zachée, Johan Maertens, et al.
Kidney International|December 12, 2018
Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical studyPauline Erpicum, Laurent Weekers, Olivier Detry, et al.
Frontiers in Genetics|October 14, 2024
Allogeneic mesenchymal stromal cell therapy in kidney transplantation: should repeated human leukocyte antigen mismatches be avoided?Suzanne Bezstarosti, Pauline Erpicum, Gianni Maggipinto, et al.
Blood Advances|July 3, 2019
Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBIArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Transfusion|June 19, 2013
Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host diseaseMuriel Hannon, Chantal Lechanteur, Sophie Lucas, et al.
Pageof 25

Showing results (161-170 of 243) with videos related to

Sort By:
Pageof 25
Frontiers in Immunology|September 15, 2018
Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD MiceGrégory Ehx, Joan Somja, Hans-Jörg Warnatz, et al.
Oncotarget|May 15, 2018
Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective studySophie Servais, Frédéric Baron, Chantal Lechanteur, et al.
Haematologica|October 12, 2010
Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of ageEmilie Castermans, Muriel Hannon, Jacques Dutrieux, et al.
Haematologica|September 28, 2014
Circadian and circannual variations in cord blood hematopoietic cell compositionSophie Servais, Etienne Baudoux, Bénédicte Brichard, et al.
Oncotarget|April 21, 2016
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myelomaRoy Heusschen, Joséphine Muller, Marilène Binsfeld, et al.
Journal of Hematology & Oncology|February 6, 2015
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological SocietyFrédéric Baron, Pierre Zachée, Johan Maertens, et al.
Kidney International|December 12, 2018
Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical studyPauline Erpicum, Laurent Weekers, Olivier Detry, et al.
Frontiers in Genetics|October 14, 2024
Allogeneic mesenchymal stromal cell therapy in kidney transplantation: should repeated human leukocyte antigen mismatches be avoided?Suzanne Bezstarosti, Pauline Erpicum, Gianni Maggipinto, et al.
Blood Advances|July 3, 2019
Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBIArnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, et al.
Transfusion|June 19, 2013
Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host diseaseMuriel Hannon, Chantal Lechanteur, Sophie Lucas, et al.
Pageof 25